Drugs / Ferrous Glycine Sulfate
Ferrous Glycine Sulfate
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy4 trials | ||||||
| Phase 4 | NCT05900635 Background | Oct 2022 → Jun 2023 | anemia due to chronic disorder | Alexandria University | Unknown | No outcome recorded |
| Phase 4 | NCT02590224 Comparator | Jan 2016 → Jul 2017 | iron deficiency anemia | Assiut University | Completed | No outcome recorded |
| Phase 4 | NCT01913808 Comparator | Jan 2011 → Feb 2012 | osteoarthritis, knee | Parc de Salut Mar | Completed | No outcome recorded |
| — | NCT02496377 Comparator | Aug 2014 → Oct 2016 | blood group incompatibility, osteoarthritis, hip, osteoarthritis, knee | University Hospital, Montpellier | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ferrous glycine sulfate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02496377 ↗ |
| Known as | Ferbisol | “Ferrous glycine sulphate (Ferbisol-Bial Industrial Farmacéutica, Spain) was given as a once daily oral dose of 100 mg iron from the day of discharge (Day 7) to the...” NCT01913808 ↗ |
| Known as | Ferrosanol duodenale capsules | “The patients will receive 567.6 mg of ferrous glycine sulphate capsules (Ferrosanol duodenale capsules, Schwarz) once daily for eight consecutive weeks.” NCT02590224 ↗ |
| Known as | ferrous glycine sulphate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01913808 ↗ |
| Known as | Tardyferon | “Drug: ferrous glycine sulfate Tardyferon” NCT02496377 ↗ |
| Route | Oral | “Daily oral dose of 100 mg iron (ferrous glycine sulphate)” NCT01913808 ↗ |